Calypte eyes China in drive to market rapid tests for HIV
This article was originally published in Clinica
Executive Summary
As part of efforts to commercialise its rapid testing platform for HIV-1/2, Calypte Biomedical has begun a clinical trial of three antibody tests in China, where the number of infections are predicted soar over the coming years.